Sai Life Sciences Ltd. was incorporated on January 25, 1999. The company is a contract research, development, and manufacturing organization (CRDMO) that offers end-to-end services across the drug discovery, development, and manufacturing value chain for small molecule new chemical entities (NCE) to global pharmaceutical and biotechnology firms.
| Bidding Dates |
|---|
| 11 Dec 2024 - 13 Dec 2024 |
| Subscription |
|---|
| 10.26x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹14,094 | 1 | 13 | 27 | 55.4 M | ₹522 - ₹549 | 35.24 % | ₹28929.8 M - ₹30426.2 M | RHP DOC |
Sai Life Sciences Ltd. IPO SUBSCRIPTION STATUS
13 Dec '24Sai Life Sciences Ltd. IPO overall subscription rate was 10.26 times the total available shares
Sai Life Sciences Ltd. IPO retail subscription rate was 1.37 times in the retail segment
Sai Life Sciences Ltd. IPO non-institutional investor subscription rate was 4.92 times in the non-institutional investor category
Sai Life Sciences Ltd. IPO Qualified Institutional Bidder subscription rate was 30.93 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
13 Dec 2024 (Day 3) | 1.37x | 4.92x | 30.93x |
12 Dec 2024 (Day 2) | 0.42x | 0.59x | 3.32x |
11 Dec 2024 (Day 1) | 0.18x | 0.15x | 2.62x |
Sai Life Sciences Ltd. FINANCIALS
| Period | Net Profit (Rs in millions) | Revenue from Operations (Rs in millions) | Cash Flow from Operations (Rs in millions) | Free Cash Flow (Rs in millions) | Margins |
| H1FY25 | 280.1 | 6,752.9 | 1,013.6 | -118.7 | 20.7% |
| H1FY24 | -129.2 | 6,423.4 | 1,212.0 | 546.9 | 11.2% |
| FY24 | 828.1 | 14,651.8 | 2,630.9 | 822.5 | 20.5% |
| FY23 | 99.9 | 12,171.4 | 2,194.0 | 1,482.4 | 15.0% |
| FY22 | 62.3 | 8,695.9 | 1,048.7 | -35.1 | 15.1% |
Sai Life Sciences Ltd. IPO SUBSCRIPTION STATUS DETAILS
Sai Life Sciences Ltd. had 55.4 M shares on offer
Sai Life Sciences Ltd. IPO offer price was in the range ₹522 - ₹549
Sai Life Sciences Ltd. IPO minimum Investment was ₹14094
Sai Life Sciences Ltd. IPO issue size was ₹ 28929.8 M - ₹ 30426.2 M
Sai Life Sciences Ltd. had a minimum lot size of 27 Shares per application
Sai Life Sciences Ltd. NUMBER OF SHARES ON OFFER
Sai Life Sciences Ltd. IPO IMPORTANT DATES
| Issue Open Date | 11 Dec 2024 |
| Issue close Date | 13 Dec 2024 |
| Allotment Date | 16 Dec 2024 |
| Refund Date | 17 Dec 2024 |
| Demat Account Credit Date | 17 Dec 2024 |
| Listing Date | 18 Dec 2024 |
| Listing on Exchange(s) | NSE and BSE |
| Sai Life Sciences Ltd. Allotment Status | Exchange |
Sai Life Sciences Ltd. IPO subscription opened on 11 Dec 2024, and closed on 13 Dec 2024
IPO allotment for Sai Life Sciences Ltd. was finalized on Monday, 16 Dec 2024
IPO listing for Sai Life Sciences Ltd. was on NSE and BSE on Wednesday, 18 Dec 2024
Sai Life Sciences Ltd. IPO LISTING GAINS
| Issue Price (adjusted) | 549.0 |
| Listing Open Price | 650.0 |
| Listing Close Price | 764.6 |
| Listing Gain% | 18.4% |
| Current Gain% | 167.4% |
Sai Life Sciences Ltd. Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sai Life Science Ltd. | 1467.9 | 30530.8 | 86.2 | 1.8 | 13.8 | 14 | 9.6 | 2241.6 | 29.5 | 348.9 | 105.1 | 17 | 48.2 |
| Sun Pharmaceutical Industries Ltd. | 1939.3 | 465303 | 38.5 | 2.3 | 7.8 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 50.4 | 16.6 |
| Divi's Laboratories Ltd. | 8425.5 | 223670.6 | 76.5 | 2.8 | 19.9 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 110.2 | 26.8 |
| Torrent Pharmaceuticals Ltd. | 4858 | 184782.7 | 84.7 | 9.5 | 11.8 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 57.3 | 8.9 |
| Cipla Ltd. | 1461.3 | 118051.6 | 35 | -0.9 | 4.2 | 11.3 | 9.1 | 29044.6 | 2.2 | 3879.2 | -26.4 | 41.7 | -37.5 |
| Zydus Lifesciences Ltd. | 1136.9 | 114398.7 | 22.7 | 2.4 | 4.2 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 50.1 | 9.6 |
Sai Life Sciences Ltd. INFORMATION ON IPO ISSUE
About Sai Life Sciences Ltd.
Sai Life Sciences Ltd. was incorporated on January 25, 1999. The company is a contract research, development, and manufacturing organization (CRDMO) that offers end-to-end services across the drug discovery, development, and manufacturing value chain for small molecule new chemical entities (NCE) to global pharmaceutical and biotechnology firms.
Object of the Issue
- Repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by the company
- General corporate purposes
Sai Life Sciences Ltd. - PROMOTERS
| Name |
|---|
| Kanumuri Ranga Raju |
| Krishnam Raju Kanumuri |
| Kanumuri Mytreyi |
| Sai Quest Syn Private Limited |
| Marigold Partners |
| Sunflower Partners |
| Tulip Partners |
| Lily Partners |
Sai Life Sciences Ltd. Book running lead manager
Kotak Mahindra Capital Company Limited
sailife.ipo@kotak.com
IIFL Securities Limited
sailife.ipo@iiflcap.com
JEFFERIES INDIA PRIVATE LIMITED
SaiLife.IPO@jefferies.com
Morgan Stanley India Company Private Limited
sailifeipo@morganstanley.com
Sai Life Sciences Ltd. Registrar to the offer
KFin Technologies Limited
sailifesciences.ipo@kfintech.com
Sai Life Sciences Ltd. Strengths
Among the largest integrated CRDMOs
The company is one of the largest integrated CRDMOs among listed Indian peers in terms of revenue from operations for FY24, serving as a one-stop platform for discovery, development, and manufacturing. (Source: F&S Report)
Diverse mix
The company provides end-to-end development and manufacturing services covering the full value chain for intermediates and APIs
Integrated discovery capabilities
The company's discovery business grew at a CAGR of approximately 34.77% from FY22 to FY24. It added 230 new customers from FY19 to FY24 and served more than 200 customers in each of the financial years 2022, 2023 and 2024
Sai Life Sciences Ltd. Risks
Requires high standards
The company's customers regularly audit and inspect its facilities, processes, and practices to ensure that the services meet their standards in the process. The company may not be able to continue to serve its customers if it fails to meet their standards in audits
Animal testing
The company conducts animal testing, which can result in adverse publicity liability and other issues, including potential disruption to its facilities as a result of protests against animal testing
Intellectual property rights
If the company inadvertently infringes on the patents or intellectual property rights of others, it may be subjected to legal action and its business and reputation may be adversely affected
IPO FAQs
This IPO consists of an offer for sale of up to Rs 2,092.6 crore, of 38,116,934 shares. It also consists of a fresh issue of Rs 950.0 crore.
The promoters of the company are Kanumuri Ranga Raju, Krishnam Raju Kanumuri, Kanumuri Mytreyi, Sai Quest Syn Private Limited, Marigold Partners, Sunflower Partners, Tulip Partners and Lily Partners.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 522.0 - 549.0.
The IPO application opens on Dec 11, 2024 and closes on Dec 13, 2024.
The minimum lot size for the IPO is 27. The maximum lot size for the IPO is 351.
For all category investors, the minimum application amount for this IPO is Rs. 14,094.0, the maximum value for this IPO is Rs 192,699.0.
This IPO will be allotted on Dec 16, 2024.
The refund will be credited to your account on Dec 17, 2024.
The allotted shares will be credited to your demat on Dec 17, 2024.
Sai Life Sciences Ltd.’s shares listed on the stock exchanges on Dec 18, 2024.